益生菌对结肠癌化疗及术后肠道菌群变化的影响以及与免疫功能下降的关系的研究被引量：12

下载PDF

导出

摘要目的探讨益生菌对结肠癌化疗及术后肠道菌群变化的影响以及与免疫功能下降的关系。方法选择我院2016年5月至2018年3月收治的195例结肠癌患者作为研究对象,随机分为对照组(98例)和观察组(97例)两组,其中对照组患者治疗后给予常规的基础治疗,观察组在对照组治疗的基础上,外加双歧杆菌四联活菌片辅助治疗,比较两组患者治疗前后免肠道屏障功能、炎症反应、免疫功能以及肠道菌群的变化。结果与治疗前相比,对照组患者双歧杆菌、乳酸杆明显减少,观察组患者明显增多;与治疗前相比,两组患者大肠杆菌、肠球菌均明显减少,而观察组减少更为显著;与治疗前相比,两组患者治疗后血浆D-乳酸、血浆DAO、L/M值、CRP、TNF-α、IL-6均明显增加,而观察组增加较少;与治疗前相比,两组患者治疗后CD3+、CD4+、CD8+、CD4+/CD8+值均明显降低,而观察组降低更少,差异均有统计学意义(P<0.05)。结论益生菌可以有效的调节结肠癌患者化疗及术后肠道菌群的平衡,减轻炎症反应,改善肠道黏膜屏障,提高机体免疫力。

作者李灼非邓兴明李粤吕国庆

机构地区北京大学深圳医院胃肠外科

出处《贵州医药》 CAS 2018年第12期1478-1480,共3页 Guizhou Medical Journal

基金深圳市卫生计生系统科研项目(项目编号:SZXJ2018084)

关键词益生菌结肠癌肠道菌群免疫功能

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1Zheng Zhang,Zhihua Liu.Paneth cells: the hub for sensing and regulating intestinal flora[J].Science China(Life Sciences),2016,59(5):463-467. 被引量：11
2张筱国,孙晓光,杨剑,葛晓明,孙年丰.不同手术方式治疗结肠癌并急性肠梗阻的疗效分析[J].贵州医药,2017,41(11):1174-1176. 被引量：18
3巩超捷,唐燕,夏璐.EGFR抑制剂对人结肠癌细胞株HT29中CD44^+细胞及侧群细胞作用的研究[J].浙江医学,2017,39(1):20-23. 被引量：2
4梁淑文,屈昌民,王晓英,李连勇,罗治文,孙焕志.益生菌治疗结肠癌患者术后化疗相关性腹泻的效果观察[J].现代生物医学进展,2014,14(24):4686-4688. 被引量：11

二级参考文献66

1Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: Impact of probiotics on diarrhea in patients treated with pelvic radiation[J]. Clin Nutr, 2013, 24(13): 274-279.
2Sharma M, Devi M. Probiotics: A Comprehensive Approach toward Health Foods[J]. Crit Rev Food Sci Nutr, 2014, 54(4): 537-552.
3De Moreno, De Leblanc A, Perdigo n G. The application ofprobiotic fermented milks in cancer and intestinal inflammation [J]. Proceedings of the Nutrition Society, 2010, 69(3): 421-428.
4Anabrees J,Indrio F, Paes B, et al. Probiotics for infantile colic: a systematic review[J]. BMC Pediatr, 2013, 13(1 ): 186-191.
5Versalovie J. The human microbiome and probioties: implications for pediatrics[J]. Ann Nutr Metab, 2013, 63(2): 42-52.
6Coyle VM, Lungulescu D, Toganel C, et al. A randomised double-bli- nd placebo-controlled phase II study of AG1004 for control of chemotherapy-induced diarrhoea [J]. Br J Cancer, 2013, 108 (5): 1027-1033.
7Mizushima T, Ide Y, Murata K, et al. A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer[J]. Ontology, 2013, 85(6): 317-322.
8Merkow RP, Bentrem DJ, Mulcahy MF, et al. Effect of Postoperative Complications on Adjuvant Chemotherapy Use for Stage III Colon Cancer[J]. Ann Surg, 2013, 258(6): 847.
9Adolph, T.E., Tomczak, M.F., Niederreiter, L., Ko, H.J., Bock, J., Martinez-Naves, E., Glickman, J.N., Tschurtschenthaler, M., Hartwig, J., Hosomi, S., Flak, M.B., Cusick, J.L., Kohno, K., lwawaki, T., Billmann-Born, S., Raine, T., Bharti, R., Lucius, R., Kweon, M.N., Marciniak, S.J., Choi, A., Hagen, S.J., Schreiber, S., Rosenstiel, P., Kaser, A., and Blumberg, R.S. (2013). Paneth cells as a site of origin for intestinal inflammation. Nature 503,272 276.
10Anderson, C.A., Boucher, G., Lees, C.W., Franke, A., D'Amato, M., Taylor, K.D., Lee, J.C., Goyette, P., Imielinski, M., Latiano, A., Lagace, C., Scott, R., Amininejad, L., Bumpstead, S., Baidoo, L., Baldassano, R.N., Barclay, M., Bayless, T.M., Brand, S., Buning, C., Colombel, J.F., Denson, L.A., De Vos, M,, Dubinsky, M., Edwards, C., Ellinghaus, D., Fehrmann, R.S, Floyd, J.A., Florin, T., Franchimont, D., Franke, L., Georges, M., Glas, J., Glazer, N.L., Guthery, S.L., Haritunians, T., Hayward, N.K., Hugot, J.P., Jobin, G., Laukens, D., Lawrance, I., Lemann, M., Levine, A., Libioulle, C., Louis, E., McGovern, D.P., Milla, M., Montgomery, G.W., Morley, K.L, Mowat, C., Ng, A., Newman, W., Ophoft; R.A., Papi, L., Pahnieri, O., Peyrin-Biroulet, L., Panes, J., Phillips, A., Prescott, N.J., Proctor, D.D., Roberts, R., Russell, R., Rutgeerts, P., Sanderson, J., Sans, M., Schumm, P., Seibold, F., Sharma, Y., Simms, L.A., Seielstad, M., Steinhart, A.H., Targan, S.R., van den Berg, L.H., Vatn, M., Verspaget, H., Waiters, T., Wijmenga, C., Wilson, D.C., Westra, H.J., Xavier, R.J., Zhao, Z.Z., Ponsioen, C.Y., Andersen, V., Torkvist, L., Gazouli, M., Anagnou, N.P., Karlsen, T.H., Kupcinskas, L., Sventoraityte, J., Mansfield, J.C., Kugathasan, S., Silverberg, M.S., Halfvarson, J., Rotter, J.l., Mathew, C.G., Griffiths, A.M., Gearry, R., Ahmad, T., Brant, S.R., Chamaillard, M., Satsangi, J., Cho, J.H., Schreiber, S., Daly, M.J., Barrett, J.C., Parkes, M., Annese, V., Hakonarson, H., Radford-Smith, G., Duerr, R.H., Vermeire, S., Weersma, R.K., and Rioux, J.D. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43. 246-252.